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Purpose

This study sought to describe the changes in immune response to a third dose of either Pfizer’s or
Moderna’s COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as
associated characteristics.

Methods

 his retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with
T
hematologic malignancies across a large Midwestern health system between August 28, 2021, and
November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to
determine serostatus.

Results

 mong 493 participants, 274 (55.6%) were seropositive both pre- and post-3V (+/+) while 115
A
(23.3%) seroconverted to positive from prior negative following the third dose (-/+). The remaining
104 (21.1%) were seronegative both before and after 3V (-/-). No participant was seropositive pre-3V
and seronegative post-3V (+/-). Results showed a statistically significant increase in the proportion of
seropositivity after receiving a third COVID-19 vaccine (P<0.00001). Response to 3V was significantly
associated with the 3V vaccine type (P=0.0006), previous COVID-19 infection (P=0.0453), and
malignancy diagnosis (P<0.0001). Likelihood of seroconversion (-/+) after 3V was higher in the group
of patients with multiple myeloma or related disorders compared to patients with lymphoid leukemias
(odds ratio: 8.22, 95% CI: 2.12–31.79; P=0.0008).

Conclusions

 third COVID-19 vaccination is effective in producing measurable seroconversion in many patients
A
with hematologic malignancies. Oncologists should actively encourage all their patients, especially
those with multiple myeloma, to receive a 3V, given the high likelihood of seroconversion. (J Patient
Cent Res Rev. 2022;9:149-157.)
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I

ndividuals who are diagnosed with certain cancers
are more likely to be at risk for COVID-19associated complications, severe morbidity, and
death.1-3 Considering one of our best tools to protect
individuals against COVID-19 is vaccination, it is of
particular concern that certain individuals are less likely to
seroconvert after the standard 2-dose COVID-19 mRNA
vaccine series manufactured by Pfizer Inc./BioNTech SE
or Moderna, Inc.4-7 With notable exceptions, patients with
hematological malignancies (HM) — more commonly
known as blood cancers such as leukemia, lymphoma, and
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multiple myeloma — seem to show a lower response to
the standard 2-dose mRNA series when compared to other
individuals with other types of cancers.8 It is thought that
the lower response to the standard 2-dose mRNA vaccine
series could be due to not only the clinical condition itself
but also adjuvant immunosuppressive treatments.4,8-10
In a study conducted with 131 patients with cancer who
received two mRNA vaccine doses, seroconversion rates
were high among the overall cohort (94%); however,
among patients with HM, seroconversion rates were
significantly lower as compared to those with solid
tumors (77% vs 98%, P=0.002).11 In another recent
study, patients with HM, particularly those receiving B
cell-depleting immunotherapy, did not gain adequate
protection from a standard 2-dose mRNA vaccine or
the 1-dose viral vector vaccination series manufactured
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by Johnson & Johnson Services, Inc.12 Likewise, in two
other studies that looked at the spike IgG antibody after
a standard 2-dose mRNA vaccine series, patients with
HM had some of the lowest responses to the vaccines.13,14
Moreover, patients with chronic lymphocytic leukemia
have shown markedly impaired immune response to
COVID-19 mRNA vaccines due to both disease activity
and treatment.15 Spike immunoglobulin G (IgG) antibody
titers tend to be highest in cancer patients who are not
receiving any cancer therapy or endocrine therapy versus
those receiving cytotoxic therapy.16,17
There is growing evidence to suggest that a third dose
of an approved COVID-19 mRNA vaccine is especially
beneficial for HM patients. This dose not only increases
the likelihood of added protection against COVID-19associated morbidity and mortality but also increases
the likelihood of seroconversion among individuals who
were unresponsive to the standard 2-dose series.18-20
Furthermore, it is now understood that achieved
vaccine-induced immunity against COVID-19 wanes
over time, leading to the need of “booster” doses.21
Given the variability of response to the 2-dose mRNA
vaccine series, it is reasonable to approach high-risk
patients with a third dose as part of their initial vaccine
strategy. When the third dose was first approved in the
United States through Emergency Use Authorization,
patients with cancer were prioritized.22 Currently,
anyone over the age of 12 is eligible for a booster dose
(be it from Pfizer-BioNTech or Moderna) irrespective
of immunocompromised status.23 Despite the universal
recommendation by the Centers for Disease Control and
Prevention (CDC) for all eligible individuals to get a
third dose, many are not doing so, with only 39% having
received a third dose as of January 20, 2022.24
This study presented herein aimed to document and
describe the changes in immune response to a third
vaccination dose of mRNA vaccine (“3V”) among
patients with HM. Data were compiled from an internal
systemwide project for which a group of hematologists/
oncologists in a large health system serving Illinois and
Wisconsin proactively reached out to their HM patient
population to encourage a 3V of either U.S. Food and
Drug Administration (FDA)-approved mRNA vaccines
for COVID-19 and to draw IgG spike protein titers preand post-3V to quantify any change in seroconversion.
Our primary objective was to quantify the proportion of
seropositivity among patients who agreed to have preand post-3V titers drawn. A secondary study objective
was to describe the characteristics of the patients in each
seroconversion category. Of note, a third COVID-19
vaccination is considered part of the primary series in
the HM patient population and the term “3V” is used to
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differentiate it from the “booster” nomenclature suggested
for immunocompetent individuals.25

METHODS

This retrospective cohort study analyzed patient data
on spike IgG antibody titers pre- and post-3V across
Advocate Aurora Health, an integrated U.S. Midwestbased health system consisting of 26 hospitals and more
than 500 sites of care. The ADVIA Centaur® SARSCoV-2 IgG (sCOVG) assay (Siemens Healthineers) was
used to provide semi-quantitative (index value) results
for the detection of IgG antibodies to the receptor-binding
domain of the S1 spike antigen of the SARS-CoV-2
virus. This assay received Emergency Use Authorization
from the FDA, and its performance characteristics
were validated internally by ACL Laboratories. Assay
sensitivity (positive result agreement) was 95.5%, and
specificity (negative result agreement) was 99.9%. An
index value of >1.00 is considered positive for SARSCoV-2 IgG antibodies.26
Participants

This study included patients who had been previously
diagnosed with HM (Table 1) within the health system
between October 31, 2019, and November 1, 2021, and
had received the full 2-dose series of a COVID-19 mRNA
vaccine, as defined by the CDC,27 4 or more weeks prior
to 3V. To be eligible for study inclusion, patients had to
have their titers drawn equal to or greater than 21 days
apart and the pre-titer had to come before or on the same
day as 3V, as part of an internal standard of care project.
Patients were excluded from the study if vaccine status
was unknown or considered incomplete or if they had
received a primary series vaccination that was not an
mRNA vaccine manufactured by Moderna and/or PfizerBioNTech. Subjects were identified via electronic medical
record (EMR) database by the research study team. This
study was deemed non-human subjects research by the
institutional review board (IRB no. 2021-214) due to the
de-identification of data to the study team.
Variables

Data in this study included demographics, mRNA vaccine
type, COVID-19 infection history prior to 3V, days
between vaccine doses, HM diagnosis, and up to 4 SARSCoV-2 IgG antibody results obtained between August 28,
2021 (the date the first titer result appeared in EMR), and
November 1, 2021, including days between the 3V of
COVID-19 vaccine and each IgG result. Age values less
than 90 years were collected as continuous, and the value
“Age 90 or older” was recoded as 90. Sex included male
and female. Race was collapsed into White, Black, Asian/
Pacific Islander, and multiracial (ie, those who identified
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Table 1.  Eligible Hematologic Malignancy Conditions
Condition

ICD-10 code

Hodgkin lymphoma
Follicular lymphoma
Nonfollicular lymphoma
Mature T/NK-cell lymphomas
Cutaneous T-cell lymphoma, unspecified
Other mature T/NK-cell lymphomas
Other specified and unspecified types of non-Hodgkin lymphoma
Other specified types of T/NK-cell lymphoma
Malignant immunoproliferative diseases and certain other B-cell lymphomas
Multiple myeloma and malignant plasma cell neoplasms
Lymphoid leukemia
Mature B-cell leukemia Burkitt-type
Other lymphoid leukemia
Myeloid leukemia
Monocytic leukemia
Other monocytic leukemia
Other leukemias of specified cell type
Leukemia of unspecified cell type
Other neoplasms of uncertain behavior of lymphoid, hematopoietic, and related tissue
Eosinophilia
Other specified disorders of white blood cells
Other and unspecified diseases of blood and blood-forming organs
Graft-versus-host disease

C81.X*
C82.X
C83.X
C84.X
C84.A
C84.Z
C85.X
C86.X
C88.X
C90.X
C91.X
C91.A
C91.Z
C92.X
C93.X
C93.Z
C94.X
C95.X
D47.X
D72.1X
D72.8X
D75.8X
D89.81X

*X indicates subcodes 1–9.
ICD-10, International Classification of Diseases, Tenth Revision; NK, natural killer.

as 2 or more races). Ethnicity included Hispanic/Latino
and non-Hispanic/Latino. Unknown values for race and
ethnicity were removed from the analysis.
COVID-19 mRNA vaccine type included PfizerBioNTech and Moderna. Days between participants’
second and third doses of vaccine was collected as
continuous. COVID-19 infection history included all
EMR-documented positive SARS-CoV-2 polymerase
chain reaction (PCR) test results for COVID-19 infection.
Diagnosis was recoded and a new category “More than
1 HM condition” was created to make the categories
mutually exclusive.
Statistical Methods

Descriptive statistics are reported as count (column
percentage) for categorical variables and as median
(range) for numeric values. Demographic and baseline
variables are also reported by IgG antibody status before/
after receiving 3V.
To assess the primary objective, a McNemar test was
used to evaluate the change in proportion of seropositive
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participants before and after receiving 3V. An exact
P-value was calculated. To assess the secondary objective,
patients were placed into three groups based on their preand post-3V seroconversion categories (-/-, -/+, and +/+).
No one went from seropositive to seronegative (+/-), so
this fourth grouping was excluded.
Categorical variables were compared using chi-squared
test or Fisher’s exact test, as appropriate, and continuous
variables using a Kruskal Wallis test, with α of P<0.05 an
indicator of statistical significance. P-values were used
to compare each variable among the three groups. Odds
ratios (ORs) were calculated for all categorical variables
comparing two groups at a time. For OR calculation, -/was used as the reference outcome because that is the most
undesirable outcome, thus, ORs compare the other two
more “desirable” results, -/+ and +/+, with -/-. Male sex,
White race, non-Hispanic/Latino ethnicity, receiving PfizerBioNTech as 3V, having previous COVID-19 infection,
and having lymphoid leukemia served as the reference
groups for those respective variables. Data management
and analysis were performed by the study team using R
statistical software (version 4.1.1, R Core Team 2021).
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RESULTS

Overall, 514 patients partially met the inclusion criteria.
Of those, 10 patients were excluded for not having 2 titer
results that were at least 21 days apart and 11 additional
patients were excluded for not having the 3V between
titers. A total of 493 patients with HM had 2 titer results
at least 21 days apart before and after receiving 3V. The
median (range) age was 71 (23–90) years, 258 (52.3%)
were male, 458 (92.9%) were White, and 479 (98.0%)
were non-Hispanic/Latino (Table 2). One patient from the

race category and 4 patients from the ethnicity category
were excluded for missing/unknown values.
As their 3V, 329 (66.7%) patients received the PfizerBioNTech and 164 (33.3%) received the Moderna. A
total of 15 (3.0%) patients had a COVID-19 infection
prior to receiving 3V. The median (range) days between
second and third doses of vaccine was 197 (29–281)
days. More than 40% of patients had more than 1 HM
condition. The most common individual conditions seen

Table 2.  Patient Demographics and Characteristics
Variable
Age in years, median (range)

N=493
71 (23–90)

Sex, n (%)
   Male
   Female

258 (52.3%)
235 (47.7%)

Race (n=492*), n (%)
   White
   Black
   Asian/Pacific Islander
   Multiracial

458 (93.1%)
26 (5.3%)
7 (1.4%)
1 (0.2%)

Ethnicity (n=489*), n (%)
   Non-Hispanic/Latino
   Hispanic/Latino origin

479 (98.0%)
10 (2.0%)

COVID-19 3V type, n (%)
   Pfizer-BioNTech
Moderna

329 (66.7%)
164 (33.3%)

COVID-19 infection pre-3V, n (%)
Yes
   No

15 (3.0%)
478 (97.0%)

Days between dose 2 and dose 3, median (range)

197 (29–281)

Clinically designated ICD-10 diagnosis, n (%)
   Lymphoid leukemia (including ALL and CLL)
   Multiple myeloma and malignant plasma cell neoplasms (including dyscrasias)
   Nonfollicular lymphoma
   Follicular lymphoma
   Myeloid leukemia (including AML and CML)
   Other specific and unspecified types of non-Hodgkin lymphoma
   Hodgkin lymphoma
   Other and unspecified diseases of blood and blood-forming organs
   Other neoplasms of uncertain behavior of lymphoid, hematopoietic, and related tissue
   Other specified disorders of white blood cells
   Malignant immunoproliferative diseases and certain other B-cell lymphomas
   Mature T/NK-cell lymphomas
>1 hematologic malignancy condition

88 (17.8%)
66 (13.4%)
44 (8.9%)
25 (5.1%)
23 (4.7%)
16 (3.2%)
9 (1.8%)
6 (1.2%)
6 (1.2%)
5 (1%)
4 (0.8%)
3 (0.6%)
198 (40.2%)

*Unknown values for race and ethnicity were removed, resulting in the reduced number of participants shown for those
variables.
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL. chronic lymphocytic leukemia; CML, chronic myeloid
leukemia; ICD-10, International Classification of Diseases, Tenth Revision; NK, natural killer.
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in the cohort were lymphoid leukemia (17.8%), multiple
myeloma and malignant plasma cell neoplasms (13.4%),
and nonfollicular lymphoma (8.9%).

Table 3. Changes in IgG Antibody Response
Pre-3V titer
result

Primary Outcome: Proportion of Seropositivity

Among 493 participants, 274 (55.6%) were seropositive
pre-3V and 389 (78.9%) were seropositive post-3V
(Table 3). Specifically, 274 (55.6%) were seropositive both
pre- and post-3V (+/+) while 115 (23.3%) seroconverted
to positive from prior negative following 3V (-/+). The
remaining 104 (21.1%) were seronegative both before
and after 3V (-/-). No participant was seropositive pre-3V
and seronegative post-3V (+/-). Results from the exact
McNemar test showed a statistically significant increase
in the proportion of seropositivity after receiving a third
COVID-19 vaccine (P<0.0001).

Post-3V titer resulta
Positive

Negative

Total

Positive

274 (55.6%)

0 (0%)

274 (55.6%)

Negative

115 (23.3%)

104 (21.1%) 219 (44.4%)

Total

389 (78.9%)

104 (21.1%)

Vaccination
status

Proportion of
seropositivity

Pre-3V

55.6%

Post-3V

78.9%

493
Pb
<0.0001c

a

Percentages out of total number of participants (n=493).

b

As determined by McNemar test.

Binomial distribution used; α of 0.05 defined significance.

c

3V, third dose of mRNA vaccine; IgG, immunoglobulin G.

Secondary Outcome: Characteristics Associated
With 3V Response

Response to 3V was significantly associated with 3V
vaccine type (P=0.0006), previous COVID-19 infection
(P=0.0453), and HM cancer type (P<0.0001) (Table 4).
Table 5 shows the odds for seroconversion (-/+) in
patients with multiple myeloma and malignant plasma
cell neoplasms were higher as compared to patients with
lymphoid leukemia (OR: 8.22, 95% CI: 2.12–31.79;
P=0.0008). The odds for being seropositive (+/+) was
greater in those who received Moderna than those who
received Pfizer-BioNTech (OR: 2.40, 95% CI: 1.42–4.02;
P<0.0008).
Within the HM diagnoses, the odds for being seropositive
(+/+) were higher in patients with multiple myeloma and
other plasma cell dyscrasias (OR: 11.40, 95% CI: 3.22–
40.31; P<0.0001), in patients with myeloid leukemia (OR:
16.36, 95% CI: 2.08–128.46; P=0.0007), and in patients
with more than 1 HM condition (OR: 1.84, 95% CI:
1.01–3.35; P=0.0447), all as compared to patients with
lymphoid leukemia (Table 5).

DISCUSSION

The COVID-19 pandemic has evolved rapidly, and
more infectious variants are becoming rapidly prevalent
worldwide. An effective vaccine strategy is still believed to
offer the best protection against severe illness, especially
for vulnerable populations.28 However, response to the
standard 2-dose mRNA vaccine strategy is not universally
effective.29,30 We present a large series of patients with
HM that shows only about 50% of these patients have
adequate IgG titer presence following standard 2-dose
mRNA vaccination. Furthermore, our data demonstrate
that over half of formerly non-seroconverted patients do
seroconvert with a 3V of either mRNA vaccine. Given
the increased risk of COVID-19-associated morbidity
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and mortality among HM patients with HM, along with
the added increased likelihood of not seroconverting
after the standard 2-dose mRNA series, it is imperative to
offer a 3V to this patient population, albeit the timing of
treatment, vaccination, and relationship to disease status
(eg stable vs progressive) is complicated.
The clinical implications of our findings recommend
that oncologists should actively encourage their patients
to receive 3V, citing this and other similar data, as
evidence of high likelihood of seroconversion and thus
more protection against severe morbidity and mortality
caused by COVID-19. This is especially true for their
those diagnosed with multiple myeloma and plasma
cell dyscrasias, patients who appear to have a high
seroconversion rate after 3V and who should consider
themselves persistently highly vulnerable to negative
outcomes following COVID-19 exposure.
Limitations of our study dataset included the lack
of T-cell function testing. Also, testing results lack
correlation to clinical outcomes due to the short timeline
between 3V and publication. Our study design did not
include accessing immunosuppressant treatment data. We
continue to follow our study population for COVID-19
infection and associated morbidity and mortality and
plan to publish such data at a future time. Future research
should explore ways to improve seroconversion, such as
with additional or higher doses of COVID-19 vaccine.
Future research also could investigate whether the
administration of different vaccine types for the first
two and third doses affects rate of seroconversion, as the
number of patients from our study falling into that camp
(n=27) was too small to adequately analyze.
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Table 4.  Patient Characteristics Associated With Paired IgG Results Before and After 3V
-/n=104 (21.1%)

-/+
n=115 (23.3%)

+/+
n=274 (55.6%)

P

Age (median, range)

72 (36–90)

72 (23–90)

70 (27–90)

0.3180

Sex
   Male
   Female

63 (60.6%)
41 (39.4%)

59 (51.3%)
56 (48.7%)

136 (49.6%)
138 (50.4%)

Racea
   White
   Black
   Asian/Pacific Islander
   Multiracial

n=104
101 (97.1%)
2 (1.9%)
1 (1.0%)
0 (0.0%)

n=115
103 (89.6%)
8 (7.0%)
3 (2.6%)
1 (0.9%)

n=273
254 (93.0%)
16 (5.9%)
3 (1.1%)
0 (0.0%)

0.1833

Ethnicitya
   Non-Hispanic/Latino
   Hispanic/Latino origin

n=104
102 (98.1%)
2 (1.9%)

n=114
112 (98.2%)
2 (1.8%)

n=271
265 (97.8%)
6 (2.2%)

>0.9999

COVID-19 3V type
   Pfizer-BioNTech
Moderna

81 (77.9%)
23 (22.1%)

85 (73.9%)
30 (26.1%)

163 (59.5%)
111 (40.5%)

COVID-19 infection pre-3V
Yes
   No

3 (2.9%)
101 (97.1%)

0 (0.0%)
115 (100.0%)

12 (4.4%)
262 (95.6%)

Days between dose 2 and dose 3 (median, range)

190 (80–260)

197 (106–276)

199.5 (29–281)

Characteristic

Diagnosis
   Lymphoid leukemia
   Multiple myeloma and malignant plasma cell
   neoplasms
   Nonfollicular lymphoma
   Follicular lymphoma
   Myeloid leukemia
   Other specific and unspecified types of non-Hodgkin
   lymphoma
   Hodgkin lymphoma
   Other and unspecified diseases of blood and bloodforming organs
   Other neoplasms of uncertain behavior of lymphoid,
   hematopoietic, and related tissue
   Other specified disorders of white blood cells
   Malignant immunoproliferative diseases and certain
   other B-cell lymphomas
   Mature T/NK-cell lymphomas
   >1 hematologic malignancy condition
a

0.1587

0.0006b

0.0453c

0.0634
<0.0001b,d

29 (27.9%)
3 (2.9%)

20 (17.4%)
17 (14.8%)

39 (14.2%)
46 (16.8%)

14 (13.5%)
8 (7.7%)
1 (1%)
5 (4.8%)

9 (7.8%)
7 (6.1%)
0 (0%)
2 (1.7%)

21 (7.7%)
10 (3.6%)
22 (8%)
9 (3.3%)

0 (0%)
0 (0%)

2 (1.7%)
2 (1.7%)

7 (2.6%)
4 (1.5%)

0 (0%)

2 (1.7%)

4 (1.5%)

0 (0%)
1 (1%)

1 (0.9%)
0 (0%)

4 (1.5%)
3 (1.1%)

1 (1%)
42 (40.4%)

1 (0.9%)
52 (45.2%)

1 (0.4%)
104 (38%)

Unknown values for race and ethnicity were removed, resulting in reduced number of participants shown for those variables.

Statistically significant at P<0.01 for chi-squared test (or Fisher's exact test) if categorical and Kruskal-Wallis test if continuous.

b

Statistically significant at P<0.05 for chi-squared test (or Fisher's exact test) if categorical and Kruskal-Wallis test if continuous.

c

d

Generated using Monte Carlo simulation with 10,000 iterations.

3V, third dose of mRNA vaccine; IgG, immunoglobulin G; NK, natural killer.
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Table 5.  Odds Ratios of Paired IgG Results Associated With Patient Characteristics
-/+ vs -/- (ref)

+/+ vs -/- (ref)

Odds ratio
(95% CI)

Pa

Odds ratio
(95% CI)

Pa

Sex
   Male
   Female

ref
1.46 (0.85, 2.50)

0.1677

ref
1.56 (0.99, 2.47)

0.0571

Race
   White
   Black
   Asian/Pacific Islander
   Multiracial

ref
3.92 (0.81, 18.92)
2.94 (0.30, 28.75)
–

0.1036
0.6216
>0.9999

ref
3.18 (0.72, 14.09)
1.19 (0.12, 11.60)
–

0.1737
>0.9999
>0.9999

Ethnicity
   Non-Hispanic/Latino
   Hispanic/Latino origin

ref
0.91 (0.13, 6.58)

>0.9999

ref
1.15 (0.23, 5.81)

>0.9999

COVID-19 3V typed
   Pfizer-BioNTech
Moderna

ref
1.24 (0.67, 2.32)

0.4932

ref
2.40 (1.42, 4.04)b

0.0008b

ref
–

0.1055

ref
0.65 (0.18, 2.35)

0.7684

0.0008b

ref
11.40 (3.22, 40.31)b

<0.0001b

0.8918
0.6881
>0.9999
0.6920

1.12 (0.49, 2.56)
0.93 (0.33, 2.65)
16.36 (2.08, 128.46)b
1.34 (0.41, 4.42)

0.7964
0.8911
0.0007b
0.6316

0.1812
0.1812

–
–

0.0388c
0.1430

0.1812

–

0.1430

0.4200
>0.9999

–
2.23 (0.22, 22.56)

0.1430
0.6359

>0.9999
0.0997

0.74 (0.04, 12.39)
1.84 (1.01, 3.35)c

>0.9999
0.0447c

Characteristic

COVID-19 infection pre-3V
Yes
   No

Diagnosis
   Lymphoid leukemia
ref
   Multiple myeloma and malignant plasma cell
8.22 (2.12, 31.79)b
   neoplasms
   Nonfollicular lymphoma
0.93 (0.34, 2.57)
   Follicular lymphoma
1.27 (0.40, 4.06)
   Myeloid leukemia
0 (0, NA)
   Other specific and unspecified types of non0.58 (0.10, 3.29)
   Hodgkin lymphoma
   Hodgkin lymphoma
–
   Other and unspecified diseases of blood and blood–
forming organs
   Other neoplasms of uncertain behavior of lymphoid,  
–
   hematopoietic, and related tissue
   Other specified disorders of white blood cells
–
   Malignant immunoproliferative diseases and certain
0 (0, NA)
   other B-cell lymphomas
   Mature T/NK-cell lymphomas
1.45 (0.09, 24.56)
   >1 hematologic malignancy condition
1.80 (0.89, 3.61)
a

Based on direct differences between the variable level relative to the reference level of the same variable.

Statistically significant at P<0.01 for chi-squared test (or Fisher's exact test).

b

Statistically significant at P<0.05 for chi-squared test (or Fisher's exact test).

b

27 patients received different vaccine types for their second and third doses. Given the small number, this analysis focused
on 3V dose type only.
d

3V, third dose of mRNA vaccine; IgG, immunoglobulin G; NA, not available; NK, natural killer; ref, reference value.
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CONCLUSIONS

A third COVID-19 vaccination is effective in producing
measurable seroconversion in many patients with
hematologic malignancy. Vaccine response was
significantly associated with 3V vaccine type, previous
COVID-19 infection, and specific HM condition. Given
these results, we believe that cancer care providers should
strongly encourage additional vaccine doses for their
patients, especially those with plasma cell disorders. For
patients with lymphoid malignancies, a single 3V vaccine
approach may not be as beneficial and other protective
approaches should be pursued (eg, antibody therapy,
postexposure antiviral therapy).
Patient-Friendly Recap
• mRNA vaccines provide robust protection against
severe illness from COVID-19. However, in patients
highly vulnerable to infection like those receiving
treatment for blood cancer, more doses may be
necessary to reach desired immunity levels.
• Authors found that more than half of patients with
hematologic malignancy whose IgG antibodies
were inadequate after 2 vaccine doses achieved
protection after a third dose.
• Given increased risk of COVID-19-associated
mortality for patients with multiple myeloma or
plasma cell disorders, oncologists should actively
encourage a 3-dose vaccine series, accounting for
treatment/disease status.
• For patients with lymphoid malignancies, a 3-dose
series may not be as beneficial and other protective
approaches should be pursued.
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